Enerpac Tool Group (EPAC) Q1 2026 earnings review
Product Sales Turn Positive, But Service Collapse Crushes Margins
Enerpac delivered a mixed bag in Q1. The good news: Core Product sales turned positive (+4% organic) for the first time in recent quarters, signaling a potential demand trough in the Americas. The bad news: Service revenue collapsed (-26% organic), primarily due to weakness in the UK. This mix shift—trading high-margin service revenue for product volume—combined with slight operating deleverage, compressed Adjusted EBITDA margins by 120bps to 22.4%. While management maintained full-year guidance, the company must now accelerate significantly in Q2-Q4 to hit targets, raising execution risk.
🐂 Bull Case
After quarters of contraction, Industrial Tools & Services (IT&S) Product sales grew 4% organically. This suggests the destocking headwinds in the core industrial market may be subsiding, particularly in the Americas.
The Biomedical segment is accelerating rapidly, posting 27% growth in Q1. While a small portion of total revenue ($6.4M), it is becoming a high-growth engine.
🐻 Bear Case
Service revenue, typically a steady compounder, plummeted 26% organically due to UK market softness. This is a massive deviation from the +5.6% growth seen a year ago and creates a hole in high-margin recurring revenue.
Gross margins fell ~70bps and Adjusted EBITDA margins compressed 120bps to 22.4%. Management cites 'lower gross margin and slight deleveraging,' indicating that cost cuts aren't keeping pace with the service revenue drop.
⚖️ Verdict: 🔴
Bearish. The return to product growth is a green shoot, but the magnitude of the service revenue collapse (-26%) and the resulting margin compression are immediate red flags. Maintaining guidance implies a steep ramp in H2 that isn't yet visible in the data.
Key Themes
Service Revenue Collapse
IT&S Service revenue dropped 26.3% organically year-over-year. Management attributed this to 'softness in the UK market,' but a drop of this magnitude implies lost contracts or project cancellations rather than just macro softness. This is a sharp reversal from the +3.4% growth seen in 25Q3 and +5.6% in 25Q1.
Core Product Sales Recovery
Reversing. For the first time in over a year, IT&S Product sales flipped to positive organic growth (+4.0%). This is the most significant positive data point in the report, suggesting that the core industrial tool business in the Americas has stabilized and is beginning to rebuild channel inventory.
Inventory Buildup
Despite sales being flat/down (-1%), Net Inventories swelled to $90.3M from $78.8M in Aug 2025 (fiscal year-end) and $81.2M in 25Q1. Rising inventory into a flat sales environment pressures working capital and risks future write-downs if demand doesn't accelerate as guided.
Cortland Biomedical Acceleration
Accelerating. Sales in the 'Other' segment (Cortland) jumped 27% to $6.4M. This validates the diversification strategy into medical/biomedical verticals, even if it remains <5% of total sales.
EBITDA Margin Erosion
Adjusted EBITDA margin fell to 22.4% from 23.6% a year ago. The company lost operating leverage on lower volume and suffered from an unfavorable mix shift (less high-margin service revenue). This breaks the trend of margin expansion seen in FY25.
Other KPIs
Reversing. Declined 0.7% YoY. Organic sales declined 1.7%, meaning the topline was propped up slightly by FX or acquisition tailwinds (DTA impact). This misses the implied run-rate needed to hit FY26 growth targets.
Accelerating. Nearly doubled from $8.6M in 25Q1. While impressive headline growth, it contradicts the net income decline, suggesting working capital timing benefits rather than core earnings power.
Stable/Low. Leverage remains pristine at 0.3x. With $139M in cash and only $188M in debt, EPAC has significant dry powder for M&A or buybacks, though they only repurchased $15M in stock this quarter.
Guidance
Maintained. Implies +3% to +6% growth vs FY25 ($616.9M). Since Q1 was -0.7%, the company effectively needs to grow ~6-7% average in Q2-Q4 to hit the midpoint. This implies a significant acceleration that the current data does not support.
Maintained. Implies ~25.2% margin at midpoint. Given Q1 came in at 22.4%, margins must expand by nearly 300bps for the remainder of the year to achieve guidance. This is a steep hill to climb given current service segment weakness.
Maintained. Implies an acceleration from FY25's $92M. Given Q1 Operating Cash Flow was $16M and CapEx was $2.7M, the run rate is decent ($13.3M FCF/quarter), but will need to pick up seasonally.
Key Questions
Service Revenue Collapse
Service revenue dropped 26% organically this quarter, attributed to 'softness in the UK.' Is this a loss of a major contract, a structural shift in the UK market, or a project timing issue that will reverse in Q2?
Path to Guidance
To hit the midpoint of your FY26 revenue guidance ($645M), you need to average roughly $167M per quarter for the rest of the year—a steep step up from Q1's $144M. What specific backlog or order trends give you confidence in this acceleration?
Inventory vs Demand
Net inventories rose to $90.3M (up 15% from year-end) while sales were flat. Is this a strategic buildup for an expected demand spike, or are products getting stuck in the channel?
Gross Margin Pressure
Gross margins compressed ~70bps YoY. How much of this is solely due to the Service mix shift versus pricing pressure in the core Product segment?